Videos

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

Tanya Dorff, MD, discusses the introduction of chimeric antigen receptor T-cell therapy into the prostate cancer landscape.

Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.

Jennifer R. Brown, MD, PhD, discusses the patient population of the SEQUOIA trial of zanubrutinib and venetoclax for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Toufic Kachaamy, MD, discusses an upcoming course that teaches the multidisciplinary approach for clinicians who have a hand in treating gastrointestinal cancers.

Stephanie Lee, MD, MPH, discusses the effectiveness of ruxolitinib within various settings for patients with chronic graft-versus-host disease.

Thomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.

Thomas C. Krivak, MD, leads a discussion on initiating antihypertensive therapy for patients with ovarian cancer who develop treatment-associated hypertension.

Experts in gynecologic oncology review the case of a 69-year-old woman with newly diagnosed high-serous carcinoma and discuss their approach to maintenance therapy after first-line chemotherapy plus bevacizumab.

Peter Martin, MD, discusses questions asked in regards to patient populations in a real-world study of treatment patterns and outcomes of mantle cell lymphoma.

Ronald S. Go, MD, explains how toxicities of treatment for histiocytic neoplasms compared with toxicities observed in other malignancies.

In an interview with Targeted Oncology™, Ming Zhao, MD, discusses the results of the FOHAIC-1 clinical trial and how it compares to HAIC-FO for the treatment of HCC.

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

Bhavana Pothuri, MD, discusses the results of the KEYNOTE-775 trial in patients with advanced endometrial cancer in relation to microsatellite instability status.

Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.

Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma

Lowell Hart, MD, FACP, discusses what he’d like to see in the future for the treatment of ER+ breast cancer and includes a note concerning Ki-67 analyses.

Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

Dr Hart explains his prognosis for our case patient.

Lowell Hart, MD, FACP, lists the different types of adverse events that are common when CDK4/6 inhibitors are used in both the adjuvant and advanced cancer setting.

Dr Hart delves into the CDK4/6 inhibitor clinical trials for breast cancer, some that he’s even participated in.

Dr Hart explains the different adjuvant therapy options for patients with HR+ breast cancer.

Lowell Hart, MD, FACP, introduces our patient case, a 54-year-old woman with ER+/PR+ breast cancer, and discusses his strategy and the risk of recurrence for the disease.

Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, share strategies for monitoring adverse events and the optimal duration for niraparib maintenance therapy for a patient with advanced ovarian cancer.

Thomas C. Krivak, MD; John K. Chan, MD; Cecelia H. Boardman, MD; and Ashley Farione, PA-C, review the optimal approach to maintenance therapeutic options for a patient with stage III, high-grade serous epithelial ovarian cancer.